The approval of oral disease modifying therapies(DMTs) for relapsing-remitting multiple sclerosis(RRMS) has changed considerably the therapeutic scenario and they often represent the first therapeutic choice for patie...The approval of oral disease modifying therapies(DMTs) for relapsing-remitting multiple sclerosis(RRMS) has changed considerably the therapeutic scenario and they often represent the first therapeutic choice for patients with RRMS,since their safety and efficacy profile has been extensively validated(D'Amico et al.,2015).展开更多
文摘The approval of oral disease modifying therapies(DMTs) for relapsing-remitting multiple sclerosis(RRMS) has changed considerably the therapeutic scenario and they often represent the first therapeutic choice for patients with RRMS,since their safety and efficacy profile has been extensively validated(D'Amico et al.,2015).
